ADDITION THERAPEUTICS

PRINT™: Precise, RNA-mediated insertion of transgenes using an R2 retrotransposase yields stable, durable, and therapeutic hepatic protein expression, from mice to NHPs

Gregory J. Cost, Ph.D.

American Society of Gene and Cell Therapy Annual Meeting, May 12th, 2026

PRINT: Combining the best of RNA therapeutics and viral gene therapies



ADDITION THERAPEUTICS

The PRINT drug substance – all-RNA and LNP



Universal Retrotransposase mRNA

Conventional mRNA

“Plug and Play” Template RNA

Proprietary sequences, Cargo agnostic

Lipid Nanoparticle

Low immunogenicity, repeat dose

ADDITION THERAPEUTICS

Precise RNA-mediated Insertion of Transgenes – how it works

All-RNA, LNP drug substance



Highly Durable DNA change



Site-specific insertion into the rDNA locus

ADDITION THERAPEUTICS

PRINT has shown over 1 year of stable expression with a single dose

in vivo

Increasing potency…

Version 1	Version 1+	Version 2	Version 2+
			
3e6	1e7	3e8	7e8

p/s

…with no loss of durability



Version 3 = an additional 4x potency increase

ADDITION THERAPEUTICS

PRINT gives flat and durable PD for >1 year with a single dose

in vivo

Flat PD give improved safety and efficacy



PRINT gives durable expression and flat PD in NHPs



Improved side effect profile by avoiding C_{max} peaks
Maximal efficacy by avoiding risk of sub-therapeutic C_{min}

Parallel increase in hematocrit from 40% to 55%

ADDITION THERAPEUTICS

PRINT's unique advantages drive our indication choice

PRINT advantage	Clinical relevance
Gene insertion	Inherited and acquired diseases
Steady serum levels	Superior efficacy and side effect profile
Strong durability	Best-suited for lifelong diseases
Redosable	Can titrate to effect

Strategy aimed at clinical indications with

- ✓ **Clear unmet needs** addressable by PRINT
- ✓ **PRINT's advantages** map to unmet need
- ✓ **Development path** pursuable by Addition
- ✓ **Success unlocks** larger indications

ADDITION THERAPEUTICS

Addition's lead indications: a rare type of obesity and Fabry disease

in vivo

PRINTing an incretin in mice



Abstract 511 – talk, Friday at 4:15

PRINTing *GLA* reduces Fabry biomarker lyso-Gb3 in KO mice



Abstract 1085 – poster, today at 5:00

ADDITION THERAPEUTICS

Addition's partnered/able indications: an anti-HIV biologic and ocular anti-VEGF

in vivo

PRINTing an anti-HIV biologic in rodents





PRINTing GFP in the rat retina









Phalloidin (RPE membrane stain)

EGFP (PRINTed transgene)

Funded in part by the Gates Foundation

Seeking partner with expertise in ocular delivery

Abstract 1347 – poster, today at 5:00

Abstract 3441 – poster, Thursday at 5:00

ADDITION THERAPEUTICS

This presentation is based on research funded by the Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Gates Foundation.

Conclusions and future events

- PRINT combines the best aspects of RNA therapeutics and conventional gene therapy
- PRINT is durable in mice for at least >1 year, NHPs for >9 months - with flat PK/PD
- Compelling preclinical data for obesity, Fabry disease, HIV, and ocular PRINTing

Coming in 2026-27

Disease-specific NHP data

Acknowledgements – it takes a village!

ADDITION THERAPEUTICS



Therapeutic Technologies



LNP Formulation



Operations



Pharmaceutical Sciences



Pre-clinical Translation